Loading
SB
Shanghai Bio-heart Biological Technology Co., Ltd. - B Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Wang Philip Li, was filed 15 May 2026.
Shanghai Bio-heart Biological Technology Co., Ltd. - B: what insiders have been doing
Shanghai Bio-heart Biological Technology Co., Ltd. - B belongs to the Health Care sector. Filings by its managers are published through HKEX. The last twelve months, up to 22 October 2026, brought 21 filings signed by 1 insider.
The flow runs one way only: 1 insider bought (21 purchases totalling €100k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 senior executive. One trade stands out by size: a purchase of €5,323 from Wang Philip Li, disclosed on 22 April 2026, or 0.0085% of market capitalisation.
Across the 1,314 companies tracked on its exchange, the median is 4 filings; at 21 filings, this issuer sits above that mark. Our records for Shanghai Bio-heart Biological Technology Co., Ltd. - B go back to 2026, with 21 purchases and no sales on the open market in total.
The last insider purchase was made public on 15 May 2026, 162 days ago. The median gap between trade and publication is zero days: most filings appear on the same day. The shorter that gap, the sooner other investors can see what insiders have done.
Elsewhere in the same sector, our signals recently picked up insider purchases at UCB. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Insider Decl.
21
Thresholds
n/a
Buy Volume
€99,815
21 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleWang Philip Li21 buys
Since the insiders bought
- -41.3%Entry HK$3.90 · Close at T+90 HK$2.29
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,171 of 26,290 companies
23.7
score / 100
Value9
Quality39
FCF yld-26%
Earn yld-24%
EV/EBITDA·
ROE-12%
Gross mgn40%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$1.18
Analyst consensus
1 analystsHK$11.75Target HK$11.75(+896%)HK$11.75
Income statement
RevenueHK$44.9M
Gross profitHK$18M40% margin
EBITDA-HK$69.1M-154% margin
Net income-HK$70.1M-196.4% margin
Valuation
PER (forward)-22.0x
P/Book0.6x
Beta0.14
Balance sheet & cash
Market capHK$287.2M
Total debtHK$12.7M
Free Cash Flow-HK$75.3M
Debt / Equity2%
Profitability & ownership
ROE-12.2%
ROA-6.6%
% insiders48.8%
% institutions10.6%
Last declaration on 15 May 2026
Declarations21 total
10,000 shares@ HK$4.000.0070% mcap4.4% of flowShareXHKGHKEX:DA20260515E00041
Canonical exit: 13 Aug 2026 (T+90)
10,000 shares@ HK$4.060.0071% mcap4.5% of flowShareXHKGHKEX:DA20260514E00013
Canonical exit: 12 Aug 2026 (T+90)
10,000 shares@ HK$4.100.0071% mcap4.5% of flowShareXHKGHKEX:DA20260513E00437
Canonical exit: 11 Aug 2026 (T+90)
10,000 shares@ HK$4.3360.0075% mcap4.7% of flowShareXHKGHKEX:DA20260512E00006
Canonical exit: 10 Aug 2026 (T+90)
10,000 shares@ HK$4.4730.0077% mcap4.9% of flowShareXHKGHKEX:DA20260511E00045
Canonical exit: 9 Aug 2026 (T+90)
10,000 shares@ HK$4.380.0076% mcap4.8% of flowShareXHKGHKEX:DA20260508E00259
Canonical exit: 6 Aug 2026 (T+90)
10,000 shares@ HK$4.360.0075% mcap4.8% of flowShareXHKGHKEX:DA20260507E00026
Canonical exit: 5 Aug 2026 (T+90)
10,000 shares@ HK$4.560.0079% mcap5.0% of flowShareXHKGHKEX:DA20260506E00010
Canonical exit: 4 Aug 2026 (T+90)
10,000 shares@ HK$4.660.0081% mcap5.1% of flowShareXHKGHKEX:DA20260505E00032
Canonical exit: 29 Jul 2026 (T+90)
10,000 shares@ HK$4.0550.0070% mcap4.4% of flowShareXHKGHKEX:DA20260430E00035
Canonical exit: 29 Jul 2026 (T+90)
10,000 shares@ HK$4.160.0072% mcap4.6% of flowShareXHKGHKEX:DA20260429E00037
Canonical exit: 28 Jul 2026 (T+90)
10,000 shares@ HK$4.060.0070% mcap4.4% of flowShareXHKGHKEX:DA20260428E00035
Canonical exit: 27 Jul 2026 (T+90)
10,000 shares@ HK$4.080.0071% mcap4.4% of flowShareXHKGHKEX:DA20260427E00036
Canonical exit: 26 Jul 2026 (T+90)
10,000 shares@ HK$4.5820.0080% mcap5.0% of flowShareXHKGHKEX:DA20260423E00019
Canonical exit: 22 Jul 2026 (T+90)
10,000 shares@ HK$4.880.0085% mcap5.3% of flowShareXHKGHKEX:DA20260422E00018
Canonical exit: 21 Jul 2026 (T+90)
10,000 shares@ HK$4.7460.0082% mcap5.2% of flowShareXHKGHKEX:DA20260421E00033
Canonical exit: 20 Jul 2026 (T+90)
10,000 shares@ HK$4.7980.0083% mcap5.2% of flowShareXHKGHKEX:DA20260420E00141
Canonical exit: 19 Jul 2026 (T+90)
10,000 shares@ HK$4.390.0076% mcap4.8% of flowShareXHKGHKEX:DA20260416E00580
Canonical exit: 15 Jul 2026 (T+90)
10,000 shares@ HK$4.510.0078% mcap4.9% of flowShareXHKGHKEX:DA20260417E00066
Canonical exit: 16 Jul 2026 (T+90)
10,000 shares@ HK$4.2890.0074% mcap4.6% of flowShareXHKGHKEX:DA20260416E00577
Canonical exit: 13 Jul 2026 (T+90)
10,000 shares@ HK$4.260.0073% mcap4.6% of flowShareXHKGHKEX:DA20260416E00579
Canonical exit: 14 Jul 2026 (T+90)
21 of 21 declarations
About Shanghai Bio-heart Biological Technology Co., Ltd. - B
Shanghai Bio-heart Biological Technology Co., Ltd. is a company focused on developing biological technologies for the healthcare sector. It is listed on the Hong Kong Stock Exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
